Resistell publishes an article in Nature Communications

Resistell, a portfolio company of Alpana Ventures, in collaboration with University Hospital Lausanne (CHUV) in Switzerland, the University Hospital Ramón y Cajal in Madrid, Spain and the Medical University of Innsbruck, Austria, has published an article in Nature Communications: « Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform » 

Resistell Nature Communications Press Release March 2024

The research was supported by grants:

• the European Union’s Accelerator grant RAPID-SEP-AST 961141
• Innosuisse Swiss Agency for the Promotion of Innovation grant 36334.1 IP-LS
• Swiss National Science Foundation (SNSF) grant CRSII5_173863
• Pfizer grant for ceftazidime-avibactam project

and Resistell’s investors: 

• Alpana Ventures
• Trumpf Venture
• Occident Group
• Zürcher Kantonalbank (ZKB) 
• EIC Fund
• Venture Kick
• and other investors

Read the article